NCT03769311View on ClinicalTrials.gov

Cetuximab in Head and Neck Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 17, 2019

Primary Completion Date

March 15, 2022

Study Completion Date

March 15, 2022

Conditions
Head and Neck CancerSquamous Cell Carcinoma
Interventions
DRUG

Cetuximab

Monoclonal antibody against epidermal growth factor receptor (EGFR)

Trial Locations (1)

53792

University of Wisconsin Carbone Cancer Center, Madison

All Listed Sponsors
collaborator

National Institute of Dental and Craniofacial Research (NIDCR)

NIH

collaborator

American Cancer Society, Inc.

OTHER

lead

University of Wisconsin, Madison

OTHER

NCT03769311 - Cetuximab in Head and Neck Cancer Patients | Biotech Hunter | Biotech Hunter